Skip to content

Study · Randomized controlled trial · 2023

7 results

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.

Lingvay I, Cheng AY, Levine JA, Gomez-Valderas E, Allen SE, Ranta K, Torcello-Gómez A, Thieu VT

Diabetes, obesity & metabolism27 Dec 2022Cited by 29 (Europe PMC)

PMID36514843 (opens in a new tab)DOI10.1111/dom.14943 (opens in a new tab)PepBankPUB-36514843
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 43% to 82% reached HbA1c below 7.0% with 5% or more weight loss and no hypoglycaemia on tirzepatide, versus 4%-5% with placebo.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on placebo reached a good HbA1c with weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <7.0% with weight loss >=5% and no hypoglycaemia versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Measurements

    Responders
    43 to 82%
    tirzepatide
    Responders
    4 to 5%
    placebo

    Source sentences

    Summary
    The proportions of participants achieving an HbA1c value of less than 7.0% with 5% or more weight loss and without hypoglycaemia ranged from 43% to 82% with tirzepatide across the SURPASS-1 to -5 trials versus 4%-5% with placebo, 51% with semaglutide 1 mg and 5% with basal insulin (P < .001 vs. all comparators).
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a higher proportion with HbA1c below 7.0%, 5% or more weight loss and no hypoglycaemia than semaglutide 1 mg (51%).

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on semaglutide reached a good HbA1c with weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <7.0% with weight loss >=5% and no hypoglycaemia versus semaglutide 1 mg
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Measurements

    Responders
    51%
    semaglutide 1 mg

    Source sentences

    Summary
    The proportions of participants achieving an HbA1c value of less than 7.0% with 5% or more weight loss and without hypoglycaemia ranged from 43% to 82% with tirzepatide across the SURPASS-1 to -5 trials versus 4%-5% with placebo, 51% with semaglutide 1 mg and 5% with basal insulin (P < .001 vs. all comparators).
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, tirzepatide gave a higher proportion with HbA1c below 7.0%, 5% or more weight loss and no hypoglycaemia than basal insulin (5%).

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on basal insulin reached good HbA1c, weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <7.0% with weight loss >=5% and no hypoglycaemia versus basal insulin
    Study

    n: not reported in source

    Comparator
    Titrated basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Measurements

    Responders
    5%
    basal insulin

    Source sentences

    Summary
    The proportions of participants achieving an HbA1c value of less than 7.0% with 5% or more weight loss and without hypoglycaemia ranged from 43% to 82% with tirzepatide across the SURPASS-1 to -5 trials versus 4%-5% with placebo, 51% with semaglutide 1 mg and 5% with basal insulin (P < .001 vs. all comparators).
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 7.0% with 10% or more weight loss and no hypoglycaemia was higher with all tirzepatide doses than with comparators.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on comparators reached good HbA1c, 10% weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <7.0% with weight loss >=10% and no hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Comparators (placebo, semaglutide, basal insulin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of participants achieving an HbA1c value of less than 7.0% with 10% or more, or 15% or more weight loss and without hypoglycaemia were significantly higher with all tirzepatide doses versus comparators across trials (P < .001 or P < .05).
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 7.0% with 15% or more weight loss and no hypoglycaemia was higher with all tirzepatide doses than with comparators.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on comparators reached good HbA1c, 15% weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <7.0% with weight loss >=15% and no hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Comparators (placebo, semaglutide, basal insulin)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportions of participants achieving an HbA1c value of less than 7.0% with 10% or more, or 15% or more weight loss and without hypoglycaemia were significantly higher with all tirzepatide doses versus comparators across trials (P < .001 or P < .05).
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more tirzepatide-treated participants than comparator participants, including semaglutide, reached HbA1c of 6.5% or less combined with weight loss and no hypoglycaemia.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on comparators reached a low HbA1c with weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <=6.5% combined with weight loss and no hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Comparator groups, including semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar results were observed for all other combinations of endpoints with an HbA1c value of 6.5% or less, or less than 5.7%, with more tirzepatide-treated participants achieving these endpoints versus those in the comparator groups, including semaglutide.
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, more tirzepatide-treated participants than comparator participants, including semaglutide, reached HbA1c below 5.7% combined with weight loss and no hypoglycaemia.

    In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on comparators reached a normal-range HbA1c with weight loss and no low blood sugar.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c <5.7% combined with weight loss and no hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Comparator groups, including semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 40 or 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar results were observed for all other combinations of endpoints with an HbA1c value of 6.5% or less, or less than 5.7%, with more tirzepatide-treated participants achieving these endpoints versus those in the comparator groups, including semaglutide.
    1 context sentence
    Summary · context
    Participants with T2D were randomized to tirzepatide (5, 10 and 15 mg), placebo (SURPASS-1,5), semaglutide 1 mg (SURPASS-2) or titrated basal insulin (SURPASS-3,4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.